Kyowa Kirin is a biotechnology and drug manufacturing company specializing in antibody technologies in core therapeutic areas such as oncology treatments for the central nervous system.
The Sanford facility is part of a larger effort to build out Kyowa Kirin’s global manufacturing network, which includes sites in Takasaki and Ube, Japan.
“The new facility will be scalable with our Takasaki Plant in Japan to help ease technology transfer between the two plants and add production capacity. We believe this will help accelerate drug development and production,” said Toshiyuki Kurata, chief supply chain officer and global manufacturing head at Kyowa Kirin.
